DOI: 10.1097/mcc.0000000000001083 ISSN:

Severe community-acquired pneumonia in the post COVID-19 era

Alfonsina Ruiz-Spinelli, Grant Waterer, Jordi Rello
  • Critical Care and Intensive Care Medicine

Purpose of review

The aim was to examine and summarize the most recent published literature in the last years stating the advances for treatment options and adjunctive therapies in patients hospitalized with severe community-acquired pneumonia (sCAP). Search was performed in PubMed, including observational studies, randomized controlled trials, systematic reviews and meta-analyses, and international guidelines.

Recent findings

Regardless of a large number of published CAP guidelines, most of their recommendations are based on low-level evidence.

Viruses have an increasing role as sCAP etiology with an impact on mortality. Accordingly, it is imperative to strengthen the demand for vaccines and newer antivirals. Considering an early monitoring of the immune response in patients with severe Influenza, may help to evaluate a personalized immunomodulatory strategy. Despite growing evidence, the use of corticosteroids as an adjunctive therapy in bacterial sCAP continues to be controversial.

Summary

Mortality due to sCAP still remains undesirably high. This fact strengthens the need for more high-quality research to increase evidence. It also highlights the need for clinicians to be aware of the level of evidence of the stated recommendations, taking this into consideration before decision making.

More from our Archive